Breast Cancer

FDA Approves Verzenio for Advanced or Metastatic Breast Cancer

By September 28, 2017

Verzenio is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6).

Potential Prognostic Biomarker ID'd for Triple-Negative Breast CA

September 26, 2017

African-American patients harbored significantly more tumor-infiltrating lymphocytes than European Americans among early-stage (I to II), but not late-stage (III to IV), patients.

Weight May Play Role in Selecting Treatment Strategy for Breast CA Patients

September 20, 2017

BMI was positively correlated with ER+/PR+ and ER−/PR− subtype risks, with a significant association only seen for ER+/PR+ subtypes.

Multivitamins Tied to Reduced Risk of Chemo-Induced Neuropathy

September 13, 2017

The researchers found that there was an association for multivitamin use before diagnosis with reduced symptoms of CIPN (CTCAE-adjusted odds ratio, 0.6 [95% confidence interval, 0.42 to 0.87]; FACT/GOG-Ntx-adjusted OR, 0.78 [95% confidence interval, 0.61 to 1]).

Handheld Pen Device Rapidly Detects Cancerous Tissue

By September 08, 2017

Researchers at the University of Texas, who developed the MasSpec Pen device, tested its capability on 20 thin tissue sections (including breast tissues, thyroid tissues, papillary thyroid carcinoma, and follicular thyroid adenoma tissues) and 253 human patient tissue samples (including lung, ovary, thyroid and breast samples) some normal and some cancerous.

Mammography Device with Patient-Assisted Compression Gets FDA Approval

By September 05, 2017

Using a handheld wireless remote control, the patient can adjust the compression force after breast positioning by a technologist.

Non-Hormone Options Recommended for Depletion After Breast CA

August 30, 2017

The researchers recommend that women should not generally be treated with menopausal hormone therapy or tibolone following breast cancer, but should optimize lifestyle.

Faslodex Monotherapy Now Approved for HR+, HER2- Advanced Breast Cancer

By August 28, 2017

The approval was supported by data from the Phase 3 FALCON trial (n=462) that enrolled postmenopausal women with HR+ metastatic or locally advanced breast cancer.

Light at Night and Breast Cancer: Is There a Link?

August 21, 2017

The team found that breast cancer levels in premenopausal women who currently smoked or had smoked in the past grew by 14% if they were in the 20% deemed to have had the most exposure to outdoor light at night.

Cancer Survival for Alternative vs. Usual Treatment Examined

August 18, 2017

Alternative medicine was independently associated with greater risk of death compared with conventional cancer treatment overall (hazard ratio [HR], 2.50), as well as in subgroups with breast (HR, 5.68), lung (HR, 2.17), and colorectal cancer (HR, 4.57).

Cancer, CV Risks Examined for Vaginal Estrogen Tx in Postmenopausal Women

By August 16, 2017

The data showed women with an intact uterus did not have a significantly different risk of stroke, invasive breast cancer, colorectal cancer, endometrial cancer, and pulmonary embolism/deep vein thrombosis (PE/DVT) between those who used vaginal estrogen and those who did not.

Gene Variation May Affect Pharmacokinetics of Breast Cancer Treatment

August 03, 2017

"Our data suggest that the OATP1B1 c.521T>C SNP may influence exemestane pharmacokinetics in humans," the authors write.

Nerlynx Available for Extended Adjuvant Tx of HER2+ Early Stage Breast Cancer

By August 01, 2017

The approval was supported by data from the Phase 3 multicenter, randomized, double-blind, placebo-controlled ExteNET trial (n=2,840) following adjuvant treatment with trastuzumab.

Two BLAs for Herceptin Biosimilars Submitted to FDA

By July 31, 2017

Two separate Biologics License Applications (BLAs) for biosimilar candidates to Herceptin (trastuzumab) have been submitted to the Food and Drug Administration (FDA).

Long-Term Recurrence Assessed in Nipple-Sparing Mastectomies

July 20, 2017

At a median follow-up of 51 months, cancer recurrence developed in 17 patients. None of the recurrences involved nipples retained during mastectomies, the researchers found.

Nerlynx Approved to Reduce Risk of Breast Cancer Recurrence

By July 18, 2017

The invasive disease-free survival was reportedly 94.2% in Nerlynx-treated patients vs. 91.9% in placebo patients after 2 years (hazard ratio [HR] 0.66, 95% CI: 0.49, 0.90; P=0.008).

FDA Committee in Favor of Herceptin Biosimilar Approval

By July 14, 2017

Herceptin, a human epidermal growth factor receptor (HER2) inhibitor, is currently approved to treat HER2-overexpressing metastatic breast cancer as a single agent in patients who have received one or more chemotherapy regimens; or in combination with paclitaxel in patients who have not received chemotherapy.

Advanced Breast Cancer Drug Granted Priority Review

By July 10, 2017

The NDA included data from two trials, MONARCH 1 and MONARCH 2, which are a part of the comprehensive MONARCH clinical trial program.

Cooling Cap FDA-Cleared to Reduce Chemotherapy-Associated Hair Loss

By July 05, 2017

A study of 122 women with Stage I and Stage II breast cancer undergoing chemotherapy particularly associated with hair loss. The study showed that over 66% of patients using DigniCap reported losing less than half their hair.

Study Addresses CA Risks For <i>BRCA1/2</i> Mutation Carriers

June 21, 2017

The researchers found that the increase in breast cancer risk rose quickly in early adulthood and then plateaued, typically for the rest of a woman's life.

Genetics Should Play a Bigger Role in Clinical Decision-Making

June 21, 2017

As home genetic testing grows, patients will be bringing their results to physicians for reaction and response. Physicians will need to be proactively prepared.

Adjuvant Capecitabine Beneficial for Certain Breast Cancer Patients

June 01, 2017

Capecitabine cut risk of relapse, death by 30 percent over five years, researchers say

Text Messaging App Helps Monitor Endocrine Tx Adherence, Side Effects

May 31, 2017

Most patients with breast cancer taking endocrine therapy report intervention helpful in taking drugs

AICR: Diet, Lifestyle Has Significant Impact on Breast CA Risk

May 24, 2017

Overall, women with the highest amounts of daily activity were 13% less likely to develop postmenopausal breast cancer, versus women with the lowest activity levels.

Study Examines ACA Impact on Early Cancer Detection

May 19, 2017

For breast cancer, the diagnosis of early disease increased from 47.8 to 48.9%. For colorectal cancer it rose from 22.8 to 23.7%. And for lung cancer from 16.6 to 17.7%.

Prevalence of Metastatic Breast Cancer Assessed in U.S.

May 18, 2017

The researchers estimate that 154,794 U.S. women are living with metastatic breast cancer, up from 105,354 in 1990.

Martial Art May Improve Insomnia, Depression in Breast CA Survivors

May 15, 2017

Researchers asked 90 breast cancer survivors with insomnia and symptoms of depression and daytime sleepiness to undergo weekly cognitive behavioral therapy sessions or weekly classes in a Westernized form of tai chi.

Kisqali Femara Co-Pack Approved by FDA

By May 08, 2017

These kinases are activated upon binding to D-cyclins and play a crucial role in signaling pathways which lead to cell cycle progression and cellular proliferation.

FDA Fast Tracks Metastatic Breast Cancer Combo Treatment

By May 08, 2017

The only adverse event that was grade 3 or higher was fatigue with 16.3% incidence in the treatment group and 13.2% in the control group.

Amneal Introduces New Strength of Thiotepa with Tepadina

By April 27, 2017

Tepadina, an alkylating agent, is indicated to reduce the risk of graft rejection when used with high-dose busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (HSCT) for pediatric patients with class 3 beta-thalassemia.